跳至主要内容
临床试验/NCT07566663
NCT07566663招募中不适用

Effect of Preventive Analgesia With Anrikefon on Postoperative Acute Pain and Rehabilitation Process in Adult Patients Undergoing Laparoscopic Cholecystectomy

Xuanwu Hospital, Beijing1 个研究点 分布在 1 个国家目标入组 274 人开始时间: 2026年6月2日最近更新:
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
274
试验地点
1

研究概览

简要总结

This study will determine the optimal timing for Anrikefon administration. It will also assess the quality of patient recovery. Laparoscopic cholecystectomy (LC) is a routine surgical procedure. However, the incidence of acute visceral and incision pain is high, reaching 50% to 70%. This pain significantly impairs patient recovery.

Anrikefon is novel peripherally restricted κ-opioid receptor agonist. It has very low brain penetration. This property reduces central nervous system side effects and respiratory depression. Preventive analgesia blocks the transmission of nociceptive stimuli to the central nervous system. It reduces postoperative pain sensitization and intensity. Currently, research on Anrikefon for preventive analgesia in LC patients is limited. It impacts on the recovery process is not yet fully understood. This study will compare drug administration before anesthesia induction with intra-operative administration.

Participants will be assigned to one of two groups with equal probability using computer-generated random numbers. Patients in the Preventive Analgesia group will receive Anrikefon injection 15 minutes before anesthesia induction. Bridging Analgesia group is the control group. Patients in this group will receive Anrikefon immediately after the gallbladder is detached from the liver. Both groups will receive the identical drug dosage of 1 μg/kg.

Both treatment groups will receive identical care beyond the time of Anrikefon administration. All patients will undergo standardized anesthesia management. Parecoxib sodium 40 mg will be injected for rescue analgesia if NRS score > 4. We will analyze the primary, secondary, and exploratory outcome measures after surgery, aiming to explore the optimal timing of Anrikefon and its impact on the patient's recovery process.

详细描述

This study is a prospective, double-blinded, randomized controlled study. Adult patients (18-65 years old) who are planning to receive Laparoscopic Cholecystectomy will be enrolled into this study, and will be randomly divided according to 1:1. They will be named the preventive analgesia group and the bridging analgesia group. Primary end point is the time-weighted sum of pain intensity differences over 0-24 hours postoperatively (SPID₀-₂₄h) , which will be calculated according to the NRS scores at every time point(after surgery immediately ,15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 20 hours, and 24 hours).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • ASA physical status classification I-III;
  • Age 18-65 years;
  • Scheduled for elective laparoscopic cholecystectomy;
  • Voluntary signed informed consent;
  • BMI between 18-28 kg/m²;
  • No history of general anesthesia surgery within the past 3 months.

排除标准

  • Severe cardiovascular disease, respiratory disease, or psychiatric disorders;
  • Severe renal insufficiency;
  • Recent use of diuretics or compound medications containing diuretics;
  • Continuous use of opioid analgesics for more than 10 days within the past 3 months;
  • Use of medications with unknown half-life affecting analgesic efficacy within 14 days prior to randomization;
  • Pregnant women, lactating women, or those planning pregnancy in the near future;
  • History of hypersensitivity to study medications.

研究组 & 干预措施

Preventive Analgesia Group

Experimental

Patients in Preventive Analgesia Group will receive intravenous Anrikefon (1 μg/kg) at 15 minutes before anesthesia induction. Each bolus administration should be completed within 2 minutes ± 5 seconds.

干预措施: Anrikefon for Preventive Analgesia (Drug)

Bridging Analgesia Group

Active Comparator

Patients in Bridging Analgesia Group will receive intravenous Anrikefon (1 μg/kg) immediately after the gallbladder is dissected from the liver bed. Each bolus administration should be completed within 2 minutes ± 5 seconds.

干预措施: Anrikefon for bridging analgesia (Drug)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验